---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-274856"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:44:16.816527+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio reports mixed Phase 2a results: AA signal, AD miss

## Summary
- SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.
- SIGNAL-AD Part B failed primary endpoint: bempikibart 74% EASI improvement vs placebo 76% (not statistically significant).
- Bempikibart safe and well tolerated in both trials; no SAEs or Grade 3+ related adverse events.
- Company plans to enroll ~20 more patients in AA expansion; defers ADX-097 AAV Phase 2 trial to focus on bempikibart.
- Biomarker data show robust Th2/Th1 reduction and 20-30% T-cell modulation, confirming target engagement.

## SEC filing metadata
- accession: 0001193125-24-274856
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312524274856/0001193125-24-274856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312524274856/d903481d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-274856
- JSON: https://secwatch.observer/filing/0001193125-24-274856.json
- Plain text: https://secwatch.observer/filing/0001193125-24-274856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.